Hepatitis A and travel amongst Nova Scotia postsecondary students: Evidence for a targeted vs. universal immunization strategy

Vaccine

Volumn 28, Issue 51, 2010, Pages 8105-8111

  Matheson, Katherine ^a,b   Halperin, Beth ^b   McNeil, Shelly ^b   Langley, Joanne M ^b   MacKinnon Cameron, Donna ^b   Halperin, Scott A ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Hepatitis A vaccine; Travel; Universal immunization

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ARTICLE; CANADA; CROSS-SECTIONAL STUDY; ENDEMIC DISEASE; ENVIRONMENTAL EXPOSURE; FEMALE; FISHER EXACT TEST; HEPATITIS A; HUMAN; IMMUNIZATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RISK FACTOR; SEROLOGY; STUDENT; TRAVEL;

ADULT; ANIMALS; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; MALE; NOVA SCOTIA; SALIVA; STUDENTS; TRAVEL; VACCINATION; YOUNG ADULT;

EID: 78649640110     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.107     Document Type: Article

References (40)

1. Koff R.S. Hepatitis A. Lancet 1998, 351:1643-1649.
2. Tong M.J., el-Farra N.S., Grew M.I. Clinical manifestations of HAV: recent experience in a community teaching hospital. J Infect Dis 1995, 171(Suppl. 1):S15-S18.
3. Tanaka A., Tujioka H., Ueda H., Hamagami H., Kida Y., Ichinose M. Autoimmune hepatitis triggered by acute HAV. World J Gastroenterol 2005, 11:6069-6071.
4. Schiodt F.V., Davern T.J., Shakil A.O., McGuire B., Samuel G., Lee W.M. Viral hepatitis-related acute liver failure. Am J Gastroenterol 2003, 98:448-453.
5. Berge J.J., Drennan D.P., Jacobs R.J., Jakins A., Meyerhoff A.S., Stubblefield A., et al. The cost of HAV infections in American adolescents and adults in 1997. Hepatology 2000, 31:469-473.
6. Centers for Disease Control and Prevention Prevention of hepatitis A through active or passive immunization. MMWR 1999, 48. [No. RR-12].
7. Centers for Disease Control and Prevention Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 55. [No. RR-7].
8. National Advisory Committee on Immunization Hepatitis A vaccine. Canadian Immunization Guide 1998, Health Canada, Ottawa, pp. 83-9. 5th ed.
9. Steffen R. Risk of hepatitis A in travelers. Vaccine 1992, 10S:69-72.
10. Steffen R., Kane M.A., Shapiro C.N., Billo N., Schoellhorn K.J., van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994, 272:885-889.
11. Nordenfelt E. Hepatitis A in Swedish travelers. Vaccine 1992, 10S:73-74.
12. Corey L., Holmes K.K. Sexual transmission of hepatitis A in homosexual men. N Eng J Med 1980, 302:435-438.
13. Valiquette L., Dion R., Bedard L. Resurgence of hepatitis A in homosexual men in Montreal centre, Quebec. Can Commun Dis Rep 1996, 22:133-136.
14. Centers for Disease Control Epidemiologic notes and reports: Hepatitis A among drug abusers. MMWR 1988, 37:297-300.
15. Harkess J., Gildon B., Istre G.R. Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87. Am J Pub Health 1989, 79:463-466.
16. Shapiro C.N., Coleman P.J., McQuillan G.M., Alter M.J., Margolis H.S. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 1992, 10S::59-62.
17. National Advisory Committee on Immunization Hepatitis A vaccine. Canadian Immunization Guide 2006, Health Canada, Ottawa, pp. 179-88. 7th ed.
18. Public Health Agency of Canada, Notifiable Diseases Online. [Accessed 29.03.10]. http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/index-eng.php.
19. Wu J., Zou S., Giulivi A. Current hepatitis A status in Canada. Can J Infect Dis 2001, 12:321-324.
20. Koff S.R. Seroepidemiology of hepatitis A in the United States. J Infect Dis 1995, 171(Suppl.):S19-S23.
21. Armstrong G.L., Bell B.P. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002, 109:839-845.
22. Centers for Disease Control and Prevention Recommended childhood immunization schedule-United States, 2001. JAMA 2001, 285:875-876.
23. Wasley A., Samandari T., Bell B.P. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005, 294:194-201.
24. Van Damme P., Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005, 294:246-248.
25. Centers for Disease Control and Prevention Recommended childhood and adolescent immunization schedule-United States. MMWR 2006, 54:Q1-Q4.
26. Gust I.D. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine 1992, 10(Suppl.):S56-S58.
27. Dillman D.A. Mail and internet surveys: the tailored design method 2000, John Wiley & Sons Inc., New Jersey (USA). 2nd ed.
28. Ochnio J.J., Scheifele D.W., Marion S.A., Bigham M., Patrick D.M., Ho M., et al. Participant-collected, mail-delivered oral fluid specimens can replace traditional serosurveys: a demonstration-of-feasibility survey of hepatitis A virus-specific antibodies in adults. Can J Public Health 2007, 98:37-41.
29. Thwe M., Frerichs R.R., Oo K.Y., Zan E., Eskes N. Stability of saliva for measuring HIV in the tropics. J Trop Pediatr 1999, 45:296-299.
30. Morris M., Cohen B., Andrews N., Brown D. Stability of total and rubella-specific IgG in oral fluid samples: the effect of time and temperature. J Immunol Meth 2002, 266:111-116.
31. Ochnio J.J., Scheifele D.W., Ho M., Mitchell L.A. New, ultrasensitive enzyme immunoassay for detection of vaccine- and disease-induced hepatitis A virus-specific immunoglobulin G in saliva. J Clin Microbiol 1997, 35:98-101.
32. Bart K.J., Orenstein W.A., Preblud S.R., Hinman A.R. Universal immunization to interrupt rubella. Rev Infect Dis 1985, 7(Suppl 1). S177-84.
33. Bonannia P., Crovarib P. Success stories in the implementation of universal hepatitis B vaccination: an update on Italy. Vaccine 1998, 16(Suppl. 1):S38-S42.
34. Coudeville L., van Rie A., Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect. 2008, 136:604-620.
35. Daniels D., Grytdal S., Wasley A. Surveillance for acute viral hepatitis-United States 2007. Surveillance Summary. MMWR 2009, 58(SS3):1-27.
36. Pham B., Duval B., Se Serres G., Gilca V., Tricco A., Ochnio J., et al. Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review. BMC Infect Dis 2005, 5:56.
37. Scheifele D.W., Ochnio J. Hepatitis A vaccine: Is it being used to best advantage?. Can Med Assoc J 2002, 167:44-45.
38. Anonychuk A.M., Tricco A.C., Bauch C.T., Pham B., Gilca V., Duval B., et al. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008, 26:17-32.
39. Bauch C.T., Anonychuk A.M., Pham B.C., Gilca V., Duval B., Krahn M.D. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007, 25:8536-8548.
40. Nova Scotia Department of Education. Nova Scotia Department of Education Annual Accountability Report For Fiscal Year 2006-2007 [Accessed 13.05,10], from http://www.ednet.ns.ca/pdfdocs/businessplan/accountability-report-2006-2007.pdf.